Arun S. Nagarajan
Expertise in
26
conditions

Dr. Arun S. Nagarajan

Hematology Oncology
2950 Cleveland Clinic Boulevard, 
Weston, FL 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
26
conditions
2950 Cleveland Clinic Boulevard, 
Weston, FL 

Overview

Arun Nagarajan is a Hematologist Oncology provider practicing medicine in Weston, Florida.

Dr. Nagarajan is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lynch Syndrome, Cholangiocarcinoma (Bile Duct Cancer), Squamous Cell Carcinoma of the Anal Canal (SCAC), Anal Cancer, and Liver Embolization.

Dr. Nagarajan is board certified in American Board Of Internal Medicine, 2004. He is actively involved in clinical research, co-authoring 31 peer reviewed articles and participating in 4 clinical trials. Dr. Nagarajan is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine, 2004

Fellowships

University of Arkansas for Medical Sciences

Hospital Affiliations

Cleveland Clinic Indian River Hospital
Cleveland Clinic
Cleveland Clinic Martin North Hospital
Cleveland Clinic Hospital

Languages Spoken

English
Hindi
Kannada

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 24 Less Insurance Carriers -

Locations

Egil and Pauline Braathen Center/Maroone Cancer Center
2950 Cleveland Clinic Boulevard, Weston, FL 33331

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

31 Total Publications

Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer.
Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer.
Journal: ESMO gastrointestinal oncology
Published: August 12, 2026
Similar Doctors
Expertise in
21
conditions
Dr. Izidore S. Lossos
Hematology Oncology | Hematology
Expertise in
21
conditions
Dr. Izidore S. Lossos
Hematology Oncology | Hematology
Referral may be required
1475 Northwest 12th Avenue, 
Miami, FL 
 (22.3 miles away)
305-243-5302
Languages Spoken:
English, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Izidore Lossos is a Hematologist Oncology specialist and a Hematologist practicing medicine in Miami, Florida. Dr. Lossos is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant. Dr. Lossos is currently accepting new patients.

Expertise in
24
conditions
Dr. Mikkael A. Sekeres
Hematology Oncology | Hematology
Expertise in
24
conditions
Dr. Mikkael A. Sekeres
Hematology Oncology | Hematology
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (22.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

His research focuses on patients with myelodysplastic syndromes (MDS) and older adults with acute myeloid leukemia (AML). Dr. Sekeres is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sekeres is currently accepting new patients.

Expertise in
26
conditions
Dr. Rafat Abonour
Hematology Oncology
Expertise in
26
conditions
Dr. Rafat Abonour
Hematology Oncology
Referral may be required
2111 Sole Mia Way 5th, 
Miami, FL 
 (18.3 miles away)
305-243-5302
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Rafat Abonour is a Hematologist Oncology provider practicing medicine in Miami, Florida. Dr. Abonour is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Transplant. Dr. Abonour is currently accepting new patients.

Frequently Asked Questions about Dr. Arun S. Nagarajan

How do I make an appointment with Dr. Arun S. Nagarajan?

You can book an appointment with Dr. Arun S. Nagarajan by calling their office at 877-463-2010. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Arun S. Nagarajan a top-rated expert for Lynch Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Arun S. Nagarajan is classified as an Distinguished expert for Lynch Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Arun S. Nagarajan specialize in?

While Dr. Arun S. Nagarajan is a Hematology Oncology, they have specific expertise in Lynch Syndrome, Cholangiocarcinoma (Bile Duct Cancer), and Squamous Cell Carcinoma of the Anal Canal (SCAC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Arun S. Nagarajan participate in research or clinical trials?

Yes. Dr. Arun S. Nagarajan has published 31 articles and abstracts on conditions like Lynch Syndrome. You can view a list of Dr. Arun S. Nagarajan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Arun S. Nagarajan accept my insurance?

Dr. Arun S. Nagarajan accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 877-463-2010 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nagarajan's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 18 Advanced Conditions
    View All 81 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile